Biogen's Al Sandrock says the FDA needs to approve their controversial Alzheimer's drug — now

Al Sandrock is an outspoken champion for aducanumab. And he clearly believes that the FDA needs to approve it now — overriding the controversy it’s sparked — or face criticism from patients clamoring for some kind of medication to slow the disease.

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE

Biogen's Al Sandrock says the FDA needs to approve their controversial Alzheimer's drug — now

This article is available only to Premium subscribers

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Novartis to cut 139 jobs in NJ as part of commercial refocus

Applied Therapeutics' rare disease drug gets a CRL

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

Bristol Myers sues the federal government over 340B, following other drugmakers

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Bio­gen's Al San­drock says the FDA needs to ap­prove their con­tro­ver­sial Alzheimer's drug — now

This article is available only to Premium subscribers

more like this

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Biogen's Al Sandrock says the FDA needs to approve their controversial Alzheimer's drug — now

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Novartis to cut 139 jobs in NJ as part of commercial refocus

Applied Therapeutics' rare disease drug gets a CRL

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

Bristol Myers sues the federal government over 340B, following other drugmakers

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy